LM-302 Injection

DRUG2 trials

Sponsors

LaNova Medicines Zhejiang Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Conditions

AdenocarcinomaAdvanced Solid Tumor

Phase 1

Study of LM-302 in Patients With Advance Solid Tumors

CompletedNCT05161390

LaNova Medicines Zhejiang Co., Ltd.Advanced Solid Tumor

Start: 2021-11-26End: 2025-01-10Updated: 2025-09-12

Phase 3

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

RecruitingNCT07385703

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Adenocarcinoma

Start: 2026-04-15End: 2030-05-01Target: 752Updated: 2026-06-25

Related Papers

A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.

Journal of Clinical Oncology2024-06-0111 citations